SCHEMBL26186755

SCHEMBL26186755

COc1cc(N(c2cc(N)ccn2)C(C)O)ccc1F

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CA P42336 2/20 0.34
▸ PIK3CD O00329 1/20 0.34
▸ ABL1 P00519 1/20 0.34
▸ EGFR P00533 1/20 0.34
▸ HCK P08631 1/20 0.34
▸ SRC P12931 1/20 0.34
▸ KDR P35968 1/20 0.34
▸ PIK3CB P42338 1/20 0.34
▸ MTOR P42345 1/20 0.34
▸ PIK3CG P48736 1/20 0.34
▸ EPHB4 P54760 1/20 0.34
▸ PRKDC P78527 1/20 0.34
▸ PI4KB Q9UBF8 1/20 0.34
▸ GRM4 Q14833 2/20 0.33
▸ KDM1A O60341 1/20 0.32
▸ KDM4C Q9H3R0 1/20 0.32
▸ HRH4 Q9H3N8 2/20 0.31
▸ ALDH1A1 P00352 2/20 0.31
▸ KIT P10721 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30285423 0.79 GRM4 (0.38) GRM4KDM4CALDH1A1KDM4EKCNH2
SCHEMBL26186417 0.79 GRM4 (0.38) GRM4KDM4CALDH1A1KDM4EKCNH2
SCHEMBL26186758 0.73 HRH4 (0.43) KDM4CHRH4ALDH1A1
SCHEMBL26186724 0.72 TSHR (0.42) HRH4ALDH1A1NOS3NOS2
SCHEMBL26186730 0.70 HRH4 (0.39) PIK3CAPIK3CDABL1EGFRHCK
SCHEMBL30285741 0.69 HTT (0.39) KDM4CALDH1A1KITKDM4EORAI1
SCHEMBL26186411 0.69 HTT (0.39) KDM4CALDH1A1KITKDM4EORAI1
SCHEMBL110676 0.66 MAPT (0.55) KDM1AALDH1A1KITKDM4E
Hydrochloric Acid SCHEMBL5745582 0.64 MAPT (0.53) KDM1AALDH1A1KITKDM4E
SCHEMBL1240000 0.64 TSHR (0.42) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230270729-A1 USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS BAYER AKTIENGESELLSCHAFT (DE) 2023-08-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230270729-A1 USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS P2RX2, P2RX4, P2RX5 PIK3CA 1376/4885PIK3CD 1394/4885ABL1 3738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback